Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2005 Oct 4:5:23.
doi: 10.1186/1471-2415-5-23.

Citalopram associated with acute angle-closure glaucoma: case report

Robert Croos  1 , Srinivasa Thirumalai, Sabit Hassan, Jane Da Roza Davis
Affiliations
Case Reports

Citalopram associated with acute angle-closure glaucoma: case report

Robert Croos et al. BMC Ophthalmol. .

Abstract

Background: Acute angle-closure glaucoma is a rare complication in patients receiving anti-depressant treatment. In the following case, we report the development of acute angle closure glaucoma in a patient who overdosed on Citalopram, an antidepressant, and discuss the possible etiological mechanisms for the condition.

Case presentation: We report a 54 year old, Caucasian lady, with depression and alcohol dependence syndrome, who developed acute angle-closure glaucoma after an overdose of Citalopram, along with alcohol. She was treated with medications and had bilateral Yag laser iridotomies to correct the glaucoma and has made complete recovery. In this case, the underlying cause for glaucoma appears to be related to the ingestion of Citalopram.

Conclusion: The patho-physiological basis for acute angle closure glaucoma in relation to antidepressant medications remains unclear. The authors suggest Citalopram may have a direct action on the Iris or Ciliary body muscle through serotonergic or anti-cholinergic mechanisms or both. This case highlights the importance of the awareness of the underlying risks, which may predispose an individual to develop acute angle-closure glaucoma, and reminds the clinicians the significance of history taking and examination of the eye before and after starting anti-depressants. This area needs to be further researched.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshelman S, Wittchen H, Kendler KS. Lifetime and 12 month prevalence of DSM-3R psychiatric disorders in the united states. Archives of General Psychiatry. 1994;51:8–19. - PubMed
    1. Lonquist J, Sutonen H, Syvalahti E, Appleberg B, Koskinen T, Maninikko T, Mehtones OP, Narala M, Shiro S, Auvinen J. Antidepressant efficacy and quality of life in Depression: A double blind study with moclobomide and Fluoxetine. Acta Psychiatrica Scandinavia. 1994;89:363–9. - PubMed
    1. Stokes PE. Fluoxetine: A five-year review. clinical therapeutics. 1993;15:216–43. - PubMed
    1. Nemeroff CB. Paroxetine: An overview of the efficacy and safety of a new selective reuptake inhibitor in the treatment of depression. Journal of clinical Psychopharmacology. 1993;13:10S–17S. - PubMed
    1. Birley M, Moret C. Neurological mechanisms involved in antidepressant therapies. Clin Neuropharmacol. 1993;16:387–400. - PubMed

Publication types

Substances

LinkOut - more resources